Emerging Frontiers in Food Allergy Treatment: Progress, Challenges, and Prospects

Abstract

Food allergy, an immune response to food, is a continuously rising and potentially deadly illness that affects millions of people around the globe. The overall immune mechanism of food allergy is described in the context of natural oral tolerance, sensitization, and desensitization. Food allergy management has traditionally focused on strict avoidance of trigger foods and the use of emergency interventions following accidental exposure. However, this approach is evolving with the emergence and development of new therapeutic strategies. Despite the alarming prevalence of food allergies, the Food and Drug Administration (FDA) has, to date, approved only two treatments: Palforzia, an oral immunotherapy for peanut allergy in children, and omalizumab, a monoclonal antibody recently approved as an adjunct therapy for food allergies. However, a growing pipeline of therapeutic options is under development, offering hope for broader and more effective interventions in the near future. This review presents an updated overview of the evolving landscape of interventional therapies for food allergy, spanning past approaches, current strategies, and future directions. It highlights advances in allergen immunotherapy and biologics, including monoclonal antibodies, tyrosine kinase inhibitors, fusion proteins, and immunoglobulin E (IgE)-disrupting agents, as well as emerging vaccine-based treatments. Additionally, the review emphasizes recent progress in gut microbiota modulation through approaches such as probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and bacteriotherapy. Other promising avenues, including the use of nanoparticle-based therapies, traditional herbal medicines, and dietary supplements, are also discussed as potential therapeutic strategies.